ANN ARBOR, Mich., June 14, 2018 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (TSX-V:ZOM) (“Zomedica” or the “Company”), a
veterinary diagnostic and pharmaceutical company, today announced the appointment of Michael Schilk as Vice President of Sales
and David Eaton as Vice President of Marketing.
Michael Schilk joins Zomedica with more than 25 years of global sales and business development experience in both
the human and animal health markets, including time at multiple Fortune 500 companies. Throughout his career, Schilk has been
responsible for leading the commercial launch of pharmaceutical and diagnostic products across North America, Europe, Asia and
Latin America and has held senior roles at Abbott Laboratories and Pfizer Inc., among others. He graduated with a Bachelor of
Science degree in economics from the University of Arizona.
David Eaton brings more than 20 years of experience leading marketing organizations both in the US and
internationally. Notably, he held senior marketing roles at animal health industry leader IDEXX Laboratories, Inc., where he was
head of international strategy and marketing for the in-house diagnostics business and later held responsibility for integrated
marketing for the $900 million US companion animal business. In addition, Eaton has held leadership roles at a number of private
and public technology companies. He attended the University of South Carolina, where he was a member of the University’s Honors
College, and studied French, Music and Journalism.
Both Schilk and Eaton will report to Bruk Herbst, Zomedica’s Chief Commercial Officer.
“We are excited to have Mike and David join our commercialization leadership team. Both bring rich experience from
the animal and human healthcare industries,” said Gerald Solensky, Jr., CEO, Zomedica. “They will be instrumental in bringing our
ever-growing portfolio of diagnostics and therapeutics to market.”
The Company also announced that Robert DiMarzo resigned as the Company’s Executive Vice President of Global
Strategy on June 12, 2018. Following that, Mr. DiMarzo has entered into a consulting agreement with Zomedica. Solensky continued,
“We wish Robert well and look forward to continuing to consult with him on our commercial development strategy.” DiMarzo added, I
believe the Company is well positioned to capitalize on the opportunities available to it in the companion animal diagnostic and
therapeutic markets, and I intend to remain available to consult on strategic issues as they may arise. I look forward to the
Company’s future success.”
About Zomedica
Based in Ann Arbor, Michigan, Zomedica (NYSE American:ZOM) (TSX-V:ZOM) is a veterinary diagnostic and pharmaceutical company
creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians.
Zomedica’s product portfolio will include novel diagnostics and innovative therapeutics that emphasize patient health and practice
health. With a team that includes clinical veterinary professionals, it is Zomedica’s mission to give veterinarians the opportunity
to lower costs, increase productivity, and grow revenue while better serving the animals in their care. For more information, visit
www.ZOMEDICA.com.
Follow Zomedica
Reader Advisory
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of the release.
Except for statements of historical fact, this news release contains certain "forward-looking information" within
the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan",
"expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or
conditions "may" or "will" occur. Although we believe that the expectations reflected in the forward-looking information are
reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results,
performance or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole
or in part, as those set out in the forward-looking information.
Forward-looking information is based on the opinions and estimates of management at the date the statements are
made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ
materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the
results to differ materially from those expressed in the forward-looking information include, but are not limited to: uncertainty
as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the likelihood and timing of
regulatory approvals, availability and cost of capital; the ability to identify and develop and achieve commercial success for new
products and technologies; the level of expenditures necessary to maintain and improve the quality of products and services;
changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; risks
pertaining to permits and licensing, intellectual property infringement risks, risks relating to future clinical trials, regulatory
approvals, safety and efficacy of our products, the use of our product, intellectual property protection and the other risk factors
disclosed in our filings with the Securities and Exchange Commission and under our profile on SEDAR at www.sedar.com. Readers are
cautioned that this list of risk factors should not be construed as exhaustive.
The forward-looking information contained in this news release is expressly qualified by this cautionary statement.
We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes
in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue
reliance on forward-looking information.
Investor Relations Contacts
Shameze Rampertab, CPA, CA
srampertab@zomedica.com
+1 647.283.3630
PCG Advisory Group
Kirin Smith, COO
ksmith@pcgadvisory.com
+1 646.863.6519
www.pcgadvisory.com
Media Contact
Andrea Eberle
aeberle@zomedica.com
+1 734.369.2555